Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 3/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066427 | 1.00 | KMT2A (0.50) | KMT2AALDH1A1KMOELANEKDM4E | |
| Oxalic Acid SCHEMBL14810479 | 0.83 | KMO (0.46) | KMT2AKMOELANEKDM4EMEN1 | |
| SCHEMBL30730294 | 0.83 | NPC1 (0.42) | KMT2AALDH1A1KMOELANEKDM4E | |
| SCHEMBL31326725 | 0.81 | KMO (0.42) | KMT2AKMOELANEMEN1NPC1 | |
| SCHEMBL18135255 | 0.81 | KMO (0.42) | KMT2AKMOELANEMEN1NPC1 | |
| SCHEMBL8725006 | 0.80 | KMO (0.43) | KMT2AKMOELANEMEN1NPC1 | |
| SCHEMBL878425 | 0.78 | RECQL (0.43) | KMT2AALDH1A1KMOELANEKDM4E | |
| SCHEMBL29350890 | 0.78 | RECQL (0.43) | KMT2AALDH1A1KMOELANEKDM4E | |
| SCHEMBL6281573 | 0.76 | ELANE (0.40) | KMT2AALDH1A1KMOELANEKDM4E | |
| SCHEMBL30918021 | 0.76 | MEN1 (0.44) | KMT2AALDH1A1KMOELANEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697203-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corporation (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2012139495-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | claimed |
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| CN-101679370-A | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | GRUENENTHAL GMBH | 2010-03-24 | — | — | CN | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| CN-1489586-A | Indazolyl-substituted pyrroline compounds as kinase inhibitor | ����-������ҩƷ��˾ | 2004-04-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | KMT2A 4539/4885ALDH1A1 1590/4885KMO 2753/4885 |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | KMT2A 4529/4885ALDH1A1 1566/4885KMO 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.